Results of Phase III (PIX306) Study Evaluating Progression-Free Survival of PIXUVRI® (pixantrone) Combined with Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma
CTI BioPharma Corp. and Servier today announced that the pivotal Phase III study (PIX306) evaluating PIXUVRI® (pixantrone) combined with rituximab in comparison to gemcitabine combined with rituximab in patients with aggressive B-cell non-Hodgkin lymphoma (NHL) did not meet its primary endpoint of improvement of progression-free survival (PFS).
“We are disappointed with the outcome of the PIX306 study and will proceed to conduct a thorough review of the clinical data to assess the next steps for the PIXUVRI program,” commented Adam Craig, MD, PhD, CEO of CTI BioPharma. “We would like to express our appreciation to the patients, families and investigators who participated in the study.”
Results will be submitted for presentation at a major scientific meeting by the end of the year and for publication in a peer-reviewed journal.
The PIX306 study is a randomized, multicenter study comparing pixantrone combined with rituximab versus gemcitabine combined with rituximab in patients with aggressive B-cell non-Hodgkin lymphoma (NHL).
The PIX306 study enrolled 312 patients who had relapsed after therapy with CHOP-R or an equivalent regimen and were ineligible for stem cell transplant. The primary endpoint was progression-free survival (PFS) while overall survival (OS), complete response rate (CR), overall response rate (ORR) and safety were secondary endpoints.
For more information about the PIX306 study, please visit
The ClinicalTrials.gov identifier is NCT01321541.
About Non-Hodgkin Lymphoma (NHL)
NHL is a blood cancer that affects the lymphatic system, which is defined as a network of vessels and glands that run throughout the body.1 The lymphatic system is a key component of the immune system, as it plays a role in destroying old or abnormal cells and fighting bacteria and other infections.2
NHL can occur in different parts of the body from the lymph nodes in the neck to the liver or spleen, but also in other organs such as the stomach, small bowel, bones, brain, testicles or skin.3 Around 168,000 new cases of NHL are diagnosed in the United States and Europe every year.
PIXUVRI® is the only treatment in the European Union indicated as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma (NHL).4 PIXUVRI® is a cytotoxic medicine that works by interfering with the DNA within cells and preventing them from making more copies of DNA. This means that the cancer cells cannot divide and eventually die.5
PIXUVRI® has not been approved by the U.S. Food and Drug Administration in the United States (US).
PIXUVRI® has conditional marketing authorization from the European Commission for prescription in the European Union (EU) as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive NHL.6 Conditional marketing authorizations are granted in the EU if all the following requirements are met: the benefit-risk balance of the product is positive, it is likely that the applicant will be able to provide comprehensive data, unmet medical needs will be fulfilled, the benefit to public health of the medicinal product's immediate availability on the market outweighs the risks due to need for further data.7 The PIX306 report will be submitted to the EMA for evaluation by the end of December 2018.
PIXUVRI® is mentioned in the ESMO guidelines as an anthracycline-like drug with reduced cardiotoxicity, which demonstrated some efficacy in heavily treated patients.8
The Summary of Product Characteristics (SmPC) has the full prescribing information, including the safety and efficacy profile of PIXUVRI® in the approved indication. The SmPC is available at www.ema.europa.eu
CTI granted Servier rights to commercialize the drug globally in all markets except the US. The two companies continue to work closely to build the efficacy and safety evidence for PIXUVRI® and to ensure that as many eligible patients as possible are benefitting from it.
Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 148 countries and a turnover of 4.152 billion euros in 2017, Servier employs 21,600 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generic drugs) in research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neuropsychiatric diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development.
Becoming a key player in oncology is part of Servier’s long-term strategy. Currently, there are nine molecular entities in clinical development in this area, targeting gastric and lung cancers and other solid tumors, as well as different types of leukemia and lymphomas. This portfolio of innovative cancer treatments is being developed with partners worldwide, and covers different cancer hallmarks and modalities, including cytotoxics, proapoptotics, immune, cellular and targeted therapies, to deliver life-changing medicines to patients.
More information: www.servier.com
Find us on Social Media:
About CTI BioPharma
CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a late-stage development pipeline, including pacritinib for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington. For additional information and to sign up for email alerts and get RSS feeds, please visit www.ctibiopharma.com.
This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," “outlook” and similar expressions, including those related to the potential therapeutic potential of PIXUVRI®, the submission of the study to a peer-reviewed journal, and the timing, scope and outcome of interactions with and submissions to regulators. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. Servier and CTI BioPharma undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond the control of either company. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in the public reports of CTI BioPharma filed with the Securities and Exchange Commission.
1 NHS Conditions webpage. NHL Cancer. Available at http://www.nhs.uk/Conditions/non-hodgkins-lymphoma/Pages/Definition.aspx [last accessed July 2018].
2 Cancer Research UK. Lymphatic System. Available at http://www.cancerresearchuk.org/about-cancer/what-is-cancer/body-systems-and-cancer/the-lymphatic-system-and-cancer [last accessed July 2018].
3 Cancer Research UK. What is NHL cancer. Available at http://www.cancerresearchuk.org/about-cancer/type/non-hodgkins-lymphoma/about/what-is-lymphoma [last accessed July 2018]
4 Pixuvri Summary of Product Characteristics, Available at: https://www.medicines.org.uk/emc/medicine/29829 [last accessed July 2018]
5 European Medicines Agency. About Pixuvri. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002055/human_med_001549.jsp&mid=WC0b01ac058001d124 [last accessed July 2018].
6 Evaluate Group. NICE Publishes Final Guidance on PIXUVRI® (pixantrone). Available at http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=490415 [last accessed July 2018].
7 European Medicines Agency. Authorisation details. Available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002055/human_med_001549.jsp&mid=WC0b01ac058001d124 [last accessed July 2018]
8 Tilly H et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology (2015). Volume 26 (suppl 5); v116-v125. Available at http://www.esmo.org/Guidelines/Haematological-Malignancies/Diffuse-Large-B-Cell-Lymphoma [last accessed July 2018]
Servier Media Relations
Tel: +33(0)1 55 72 40 21/+33(0)7 84 28 76 13
Tel: +33(0)1 55 72 60 37
Julia Balanova (investors)
Tel: +1 646 378 2936
Rich Allan (media)
Tel: +1 646 378 2958
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Corsair Infrastructure Partners Announces Transaction Involving DP World Australia23.1.2019 04:35 | Pressemelding
Corsair Infrastructure Partners (“CIP”), the global infrastructure investment business of Corsair Capital (“Corsair”), today announced that Gateway Infrastructure Investments (“Gateway”), an investment fund managed by CIP, as well as several other financial investors, have entered into agreements to sell their entire stakes in DP World Australia (Holding) Pty Ltd (“DPWA”) to DP World and new investment funds managed by CIP. The closing of the transaction is subject to regulatory approvals. As a result of this transaction, DP World, the original corporate parent of DPWA, will hold a majority stake in the company, alongside a substantial minority investment by CIP-managed funds. Hari R. Rajan, Managing Director of Corsair and Head of CIP, said, “We are pleased to have achieved the exit of Gateway’s investment in DPWA, while maintaining our strong relationship with DP World through our continued management of a large investment in the company. We believe this new shareholder structure wil
Yokogawa Joins Global 100 Most Sustainable Corporations in the World Index23.1.2019 04:00 | Pressemelding
Yokogawa Electric Corporation (TOKYO:6841) announces that it has been included in the 2019 Global 100 Most Sustainable Corporations in the World Index (Global 100). This is Yokogawa’s first time on the Global 100, one of the world's leading sustainability indices. Now in its 15th year, the 2019 Global 100 was disclosed in Davos on January 22nd by Corporate Knights, a Canadian media and research company focused on clean capitalism, to coincide with the World Economic Forum. To determine the 2019 ranking, Corporate Knights undertook a rigorous analysis of more than 7,500 companies with US$1B+ in revenues against global industry peers on a suite of up to 21 quantitative key performance indicators, weighted to reflect each industry’s impact profile. Yokogawa was ranked in the top 25% in both the clean revenues* and innovation capacity categories. In its core industrial automation and control business, Yokogawa works with customers in the energy, chemical, iron and steel, water, and other i
V-CAT to Begin a New Type of Crowdfunding, Using Digital Currency23.1.2019 00:00 | Pressemelding
V-CAT Vietnam will develop a new type of crowdfunding services that uses digital currency. A platform that uses the JC-coin digital currency will be built, and all data involved in transactions will be safely protected with leading-edge blockchain technology. Any user with JC-coins can exchange any physical or digital assets they might own on the platform for more JC-coins. This will provide the funding needed to develop revolutionary new products and services, together with users worldwide, and will enable new investments in all kinds of different businesses. V-CAT is proceeding with development of the MALLLESS platform in advance of an April 2019 launch of services. The goal is to host 10 million users worldwide by 2020. What makes MALLLESS unique is that businesses and individuals can take advantage of the point-transfer transaction model website and the proprietary wallet mechanism, both of which enable any selling of new or used goods, or of intangibles. There is also conversions
Prominent Trade Consulting Firm in South Korea Switches to Rimini Street Support for Its Oracle Database22.1.2019 23:00 | Pressemelding
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced that EC21, a leading export marketing and trade consulting firm in Korea, has switched to Rimini Street support for its Oracle Database software. By switching to Rimini Street, EC21 is able to dramatically reduce the total cost of maintenance of its Oracle Database by approximately 75 percent, and improved productivity within its IT department as resources can be reallocated to more strategic projects across the organization. EC21 can also maintain its robust, stable database platform for a minimum of 15 years from the time the company moved to Rimini Street, avoiding any unnecessary upgrades just to retain full support from the vendor. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190122005104/en/ Prominent Trade Consulting Fir
IFF to Release Fourth Quarter and Full Year 2018 Results February 1322.1.2019 21:15 | Pressemelding
Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of scent, taste, and nutrition, announced that it will release its fourth quarter and full year 2018 earnings results following the market close on Wednesday, February 13, 2019. The management team will host a live webcast on Thursday, February 14, 2019 at 10:00 a.m. ET to discuss results and outlook with the investor community. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Meet IFF International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF) is a leading innovator of scent, taste, and nutrition, with over 110 manufacturing facilities, 100 R&D centers, and 33,000 customers globally. At the heart of our company, we are fueled by a sense of discovery, constantly asking “what i
Gilead Sciences to Release Fourth Quarter and Full Year 2018 Financial Results on Monday, February 4, 201922.1.2019 21:05 | Pressemelding
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2018 financial results will be released on Monday, February 4, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the fourth quarter and full year 2018 and provide a business update. The live webcast of the call can be accessed at the company’s Investors page at http://investors.gilead.com/. Please connect to the company’s website at least 15 minutes prior to the start of the call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call 877-359-9508 (U.S.) or 224-357-2393 (international) and dial the conference ID 3826138 to access the call. Telephone replay will be available approximately two hours after the call through 8:00 p.m. Eastern Time, February 6, 2019. To access the replay, please call 855-859-2056 (U.S.) or 404-537-3406 (int